A blueprint for pharmacy benefit managers to increase value

American Journal of Managed Care

Volumn 15, Issue 2, 2009, Pages 87-93

  Shrank, William H ^a,b   Porter, Michael E ^c   Jain, Sachin H ^c   Choudhry, Niteesh K ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD BUSINESS SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROMOTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL; REVIEW; UNITED STATES;

COST CONTROL; COST-BENEFIT ANALYSIS; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICATION ADHERENCE; PHARMACY ADMINISTRATION; QUALITY ASSURANCE, HEALTH CARE; TIME FACTORS;

EID: 61849164595     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Porter ME, Teisberg EO. Redesigning Healthcare: Creating Value-Based Competition in Results. Boston, MA: Harvard Business School Press; 2006.
2. Atlas RF. The role of PBMs in implementing the Medicare prescription drug benefit. Health Aff (Millwood). 2004;Suppl Web Exclusives:W4504-W4515.
3. Osterberg L, BlaschkeT. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
4. Shrank WH, Asch SM, Adams J, et al. The quality of pharmacologic care for adults in the United States. Med Care. 2006;44(10):936-945.
5. National Council on Patient Information and Education. Enhancing Prescription Medicine Adherence: A National Action Plan. August 2007. http://www.talkaboutrx.org/documents/enhancing-prescription-medicine- adherence.pdf. Accessed May 12, 2008.
6. Wiseberg Brin D. Drug-benefit firms offer hand. Wall Street Journal. September 17, 2008.
7. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: WHO; 2003. http://www.who.int/chp/ knowledge/publications/adherence-report/en/index.html. Accessed May 12, 2008.
8. Benner JS, Glynn RJ, Mogun H, Neuman PJ, Weinstein MC, Avom J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461.
9. Caro JJ, Saias M, Speckman JL, Raggio G. Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1):31-37.
10. Choudhry NJ, Patrick AR, Antman EM, Avom J, Shrank WH. The cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261-1268.
11. Huskamp HA, Deverka PA, Epstein AM, Epstein RA, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
12. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-2194.
13. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, andTreatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
14. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30:S4-S41.
15. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142(11):891- 897.
16. Fischer MA, Avom J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850-1856.
17. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21 ):2514-2526.
18. Shrank WH, HoangT, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
19. Wang PS, Simon GE, Avom J, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA. 2007;298(12):1401-1411.
20. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
21. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-112.
22. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166(3): 348-354.
23. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
24. Kripalani S,Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540-550.
25. Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Aff (Millwood). 2007;26(3):731-740.
26. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22(11 ):1572-1578.